arrow
E

Enrique Gallardo

Institut d'Investigacio i Innovacio Parc Tauli
H指数:29
被引数:4,830

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Prognostic value of PD-L1 in patients with metastatic renal cell carcinoma (mRCC) treated with antiangiogenic first line drugs (PROANG-SOGUG study)

PD-L1在采用抗血管生成一线药物治疗转移性肾细胞癌(mRCC)患者中的预后价值(PROANG-SOGUG研究)

2026-09-280
PRE
Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer.

EORTC 1333/PEACE-3试验的恩扎鲁他胺加镭-223治疗转移性去势抵抗性前列腺癌的最终总生存期结果。

2026-02-260
OAAI
A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastases

EORTC 1333/PEACE-3研究的通俗摘要:恩扎卢胺单药与恩扎卢胺联合镭-223治疗伴有骨转移的转移性去势抵抗性前列腺癌(mCRPC)患者的比较研究

2025-11-010
PRE
Balancing risks and benefits of immune checkpoint inhibitors in patients with pre-existing immune-mediated inflammatory diseases: A comprehensive review

权衡免疫检查点抑制剂在存在基础免疫介导性炎症性疾病患者中的风险与获益:一项综合综述

2025-10-300
PRE
Therapeutic Alliances for Optimizing the Management of Patients with Prostate Cancer: SOGUG Multidisciplinary Expert Panel Recommendations

优化前列腺癌患者管理的治疗联盟:SOGUG多学科专家小组建议

2025-10-010
OAAI
Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study

卡博替尼治疗晚期肾细胞癌在西班牙和葡萄牙真实世界实践中的有效性与安全性:SOGUG-SPRWEC研究

2025-09-010
PRE
Clinical advances and practice updates in genitourinary cancers: a 2024 review from the multidisciplinary Spanish 'Cambados annual meeting' ( Feb , 10.1007/s12094-025-03850-z , 2025)

泌尿生殖系统肿瘤的临床进展与实践更新:西班牙多学科“坎巴多斯年会”2024年综述(2025年2月,10.1007/s12094-025-03850-z)

2025-04-040
PRE
Clinical advances and practice updates in genitourinary cancers: a 2024 review from the multidisciplinary Spanish 'Cambados annual meeting'

泌尿生殖系统癌症的临床进展与实践更新:西班牙多学科“坎巴多斯年会”2024年综述

2025-02-170
PRE
Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial

在一线醋酸阿比曲酮或恩扎鲁他胺治疗无症状骨转移的转移性去势抵抗性前列腺癌患者的镭223: 一项单臂II期试验

2022-09-017
PRE
Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study
2022-06-016
OAAI